Hans Moebius
Chief Tech/Sci/R&D Officer chez Exciva GmbH
Fortune : 250 661 $ au 31/03/2024
Profil
Hans Moebius is the founder of Exciva GmbH, which was founded in 2016.
He held the position of Chief Executive & Medical Officer from 2016 to 2019.
Currently, he is the Chief Medical Officer at Exciva GmbH since 2020.
Dr. Moebius's former positions include Executive Vice President-Clinical Research at Chase Pharmaceuticals Corp.
and Chief Medical Officer at Athira Pharma, Inc. from 2019 to 2024 and at Rodin Therapeutics, Inc. from 2016 to 2018.
Dr. Moebius received his doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1983 and his undergraduate degree from Technische Universität Kaiserslautern in 1976.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ATHIRA PHARMA, INC.
0,24% | 04/01/2024 | 91 482 ( 0,24% ) | 250 661 $ | 31/03/2024 |
Postes actifs de Hans Moebius
| Sociétés | Poste | Début |
|---|---|---|
Exciva GmbH
 Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
Anciens postes connus de Hans Moebius
| Sociétés | Poste | Fin |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Tech/Sci/R&D Officer | 05/01/2024 |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Chief Executive Officer | 01/01/2019 |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/04/2018 |
Chase Pharmaceuticals Corp.
 Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Chief Tech/Sci/R&D Officer | 01/01/2016 |
Formation de Hans Moebius
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| Technische Universität Kaiserslautern | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ATHIRA PHARMA, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Chase Pharmaceuticals Corp.
Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC. | Health Technology |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | Commercial Services |
